T Cell Staining Reagents
imusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read more
Oncology
GSK’s ADC Blenrep Cuts Risk of Multiple Myeloma Progression by Nearly 50% in Phase III Trial
British pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read more
AstraZeneca to Build $1.5B ADCs Manufacturing Facility in Singapore
In a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a
Read more
Recombinant HLA Proteins
imusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more
Peptide Binding Analysis
imusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read more
NIH Researchers Improve Cancer Drug Response Prediction Using scRNA-seq Data AI Model
In a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read more
Nutcracker’s mRNA Drug Candidate for Prostate Cancer Effectively Targets CD3 T cells
Preclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read more
FDA Approves J&J and Bristol Myers Cell Therapies for Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read more
US FDA Approves First Tumor-agnostic HER2-directed Therapy
The US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read more
FDA Greenlights Iovance’s AMTAGVI™ as First T-cell Therapy for Solid Tumor Cancer
Iovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read more